



# RAPID ALERT

DRAP ALERT No: I/S/05-25-42

## CRACKDOWN AGAINST FALSIFIED / SPURIOUS DRUGS

**Date:** 19<sup>th</sup> May, 2025

### Target Audience:

- Regulatory Field Force of DRAP and Provincial Drug Control departments.
- Healthcare Professionals
- Pharmacies and medical stores

### Problem Statement:

Directorate of Drug Control Punjab (DDCP) has informed Drug Regulatory Authority of Pakistan that the samples of below mentioned products have been declared '*Spurious*'. The details of reports are as under:

S#	Product Name	Batch No.	Purported Manufacturer	Remarks
1.	<b>Cefim Capsule 400mg</b>  Each capsule contains: Cefixime as trihydrate USP...400mg	150994	<b>M/s Hilton Pharma (Pvt.) Ltd.,</b> Plot No. 13-14, Sector 15, Korangi Industrial Area, Karachi.	'Spurious' as per Section 3(z-b) (i) and (ii) of the Drugs Act, 1976.
2.	<b>Acefyl Cough Syrup 125mL</b>  Each 5ml contains: Acefylline Piperazine.....45mg Diphenhydramine HCL.....8mg	ACG753	<b>M/s Nabiqasim Industries (Pvt.) Ltd.,</b> 17/24, Korangi Industrial Area, Karachi.	'Spurious' as per Section 3(z-b) (i) and (ii) of the Drugs Act, 1976.
3.	<b>DROPHA-10 Tablet</b>  Each film coated tablet contains: Dydrogesterone.....10mg	DRP-0012	<b>M/s Himax Pharmaceutical.,</b> Plot No. 445, Korangi Industrial Area, Karachi.	'Spurious' as per Section 3(z-b) (i) of the Drugs Act, 1976.
4.	<b>Dydrocare 10mg Tablet</b>  Each film coated tablet contains: Dydrogesterone.....10mg	DC-0003-Y	<b>M/s Carryfor Pharmaceuticals (Pvt.) Ltd.,</b> Plot No. E-81, North Western Industrial Zone, Port Qasim, Karachi.	'Spurious' as per Section 3(z-b) (i) of the Drugs Act, 1976.



DRAP, Islamabad

+ 92 051 9255969

gsms@dra.gov.pk



5.	<b>Dydroplax 10mg Tablet</b>  Each film coated tablet contains: Dydrogesterone.....10mg	DDP-0491-X	<b>M/s Carryfor Pharmaceuticals (Pvt.) Ltd.,</b> Plot No. E-81, North Western Industrial Zone, Port Qasim, Karachi.	<b>‘Spurious’</b> as per Section 3(z-b) (i) of the Drugs Act, 1976.
----	--	------------	--	---

#### **Risk Statement:**

Falsified products having no active ingredient or identification of manufacturer pose a great risk to the health of patient and can cause adverse drug reactions or may lead to therapy failure that can result in fatal consequences.

#### **Action Initiated: -**

The Regulatory Field Force of DRAP and Provincial Drug Control Departments has been directed to conduct surveillance activities throughout the supply chain to confiscate the falsified products.

#### **Advice for Healthcare Professionals: -**

DRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using [Adverse Event Reporting Form](#) or online through this [link](#). Further information on reporting problems to DRAP is available on this [link](#).

#### **Advice for Consumers:**

Consumers should not use these products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre.

All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.



**Drug Regulatory Authority of Pakistan**

محفوظ، موثر اور معیاری اشیائے علاج

